Paolo Bottini

Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ.

Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom.

New York Philharmonic provides live theatrical presentations. The company was founded in 1842 and is headquartered in New York, NY.

CEO Roundtable on Cancer, Inc. promotes activities to reduce cancer risk, enable early detection, facilitate better access to treatment and hasten the discovery. Its programs include CEO cancer gold standard, life sciences consortium and project data sphere. The company was founded by George H. W. Bush in 2001 and is headquartered in Durham, NC.

Part of Eisai Co., Ltd., Eisai Corp. of North America is a pharmaceutical company that manufactures pharmaceutical products. The private company is based in Woodcliff Lake, NJ.

Swiss-American Chamber of Commerce is an organization that advocates for Swiss, American, and multinational business interests. The non-profit company is based in Zurich, Switzerland. The Swiss company is active in all three major regions of Switzerland, organizing events and conducting comprehensive studies on business-related topics. The organization's special committees provide valuable input into its operations, and its flagship publication, the Yearbook, contains a member directory and a comprehensive collection of facts and figures on Swiss-U.S. business relations. Martin M. Naville has been the CEO of the company since 2004.

The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium.

Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016.

MGI PHARMA Biologics, Inc. develops and markets pharmaceutical and medical therapies. The company's products amolimogene and ZYC300 represent a breakthrough in the activition of cytotoxic cells. The company was founded in 1979 and is located in Lexington, MA

Italfarmaco SpA engages in the production and distribution of pharmaceutical and fine chemical products. It also provides research and development, scientific publishing, business development, and licensing services. The company was founded in 1938 and is headquartered in Milan, Italy.

Helsinn Therapeutics (U.S.), Inc. develops, manufactures and supplies pharmaceutical products for treatment of cancer. The company is headquartered in Iselin. NJ.

Quanta Dialysis Technologies Ltd. develops haemodialysis systems. The firm's SC+ is a performance, portable, compact haemodialysis system providing clinical efficacy utilising flow rates typically used on traditional machines. It offers SelfCare+, a haemodialysis machine for dialysis patients to control their disease and determine the treatment regime and care. The company was founded by Clive Henrey Buckberry, John Eric Milad and Martin Johnson in 2008 and is headquartered in Alcester, the United Kingdom.

BSP Pharmaceuticals SpA develops and manufactures anticancer drugs. It offers development, clinical supply, commercial supply, and analytical services. The company was founded by Aldo Braca in July 2006 and is headquartered in Latina Scalo, Italy.

Helsinn Birex Pharmaceuticals Ltd. develops and manufactures oral dosage drug products. It is engaged in providing oral solid dosage forms and topical forms of pharmaceutical products and packaging of sterile products. The firm supplies its partners with ready to sell products on an exclusive basis, which are manufactured on site and using a network of external manufacturing partners. The company was founded by Gabriele Braglia on May 18, 1978 and is headquartered in Dublin, Ireland.

WellnessFX, Inc. provides online nutrition services for improving personal health. Its services include blood tests, phone consultations with health practitioners and intuitive online data tracking to measure cardiovascular, metabolic, hormonal and nutritional needs for health. The company was founded by Jim Kean and Brent Vaughan in 2010 and is headquartered in San Francisco, CA.

Prismic Pharmaceuticals, Inc. engages in the research and development of prescription drugs for kidney disease, mental health, and chronic pain. It also offers medical foods for patients with chronic kidney disease, and depression and bipolar disorder. The company was founded by Zachary Dutton, Danilo Casadei Massari, and Peter J. Moriarty in 2011 and is headquartered in Worcester, MA.

Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom.

Helsinn Healthcare SA /Venture/ is a Venture Capital firm, a subsidiary of Helsinn Healthcare SA founded in 1992. Helsinn Healthcare SA /Venture/ is headquartered in Luxembourg.

Greenbone Ortho SRL develops a wood-derived bone implants technology to generate biomimetic implant suitable to address non-union fractures. It offers GreenBone that reproduce chemical composition and thee-dimensional architecture of natural tissues. The company was founded by Lorenzo Pradella in 2014 and is headquartered in Faenza, Italy.

QuantuMDx Group Ltd. develops devices for diagnostics detection. The firm offers DNA-XT, Under The Tree Diagnostics, Q-POC, and Internet of Life. The company was founded by Jonathan O'Halloran, Elaine Warburton, and Julian Warburton in March 2008 and is headquartered in Newcastle upon Tyne, the United Kingdom.

Micromega Ltd. provides business support services. The private company is based in London, UK. The British company was founded by Francesco Granata.

Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections.

Diadem Srl predicts, monitors, diagnosis and drug development for Alzheimer?s disease. focuses on specific research on early peripheral markers of Alzheimer's disease into technology. The company was founded by Maurizio Memo and Daniela Uberti in June 2012 and is headquartered in Brescia, Italy.

The National Centre for Research and Development in Poland provides executive agency services.

3B Future Health Fund II S.C. A. SICAV-RAIF invests in companies located in the US, Europe, Israel and Japan. The fund target companies operating in the fields of healthcare. It provides financing for early stage capital requirements with an investment up to EUR 10.17 million ($12 million) per company. It also makes follow on investment and take a seat on the board of director.